These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27546726)

  • 21. Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors.
    Yang Y; Mandiyan S; Robinson BS; McMahon G
    Cancer Res; 2016 Oct; 76(19):5788-5797. PubMed ID: 27550450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody.
    Watanabe Y; Asano R; Arai K; Shimomura I; Ogata H; Kawaguchi H; Hayashi H; Ohtsuka H; Yoshida H; Katayose Y; Egawa S; Nakanishi T; Umetsu M; Yasui H; Ishida T; Imai K; Kudo T; Unno M; Kumagai I
    Oncol Rep; 2011 Oct; 26(4):949-55. PubMed ID: 21743971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.
    Wang J; Goetsch L; Tucker L; Zhang Q; Gonzalez A; Vaidya KS; Oleksijew A; Boghaert E; Song M; Sokolova I; Pestova E; Anderson M; Pappano WN; Ansell P; Bhathena A; Naumovski L; Corvaia N; Reilly EB
    BMC Cancer; 2016 Feb; 16():105. PubMed ID: 26879245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells.
    Piccione EC; Juarez S; Liu J; Tseng S; Ryan CE; Narayanan C; Wang L; Weiskopf K; Majeti R
    MAbs; 2015; 7(5):946-56. PubMed ID: 26083076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity.
    Shi SY; Lu YW; Liu Z; Stevens J; Murawsky CM; Wilson V; Hu Z; Richards WG; Michaels ML; Zhang J; Yan W; Li Y
    J Biol Chem; 2018 Apr; 293(16):5909-5919. PubMed ID: 29483191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
    Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
    Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties.
    Bezabeh B; Fleming R; Fazenbaker C; Zhong H; Coffman K; Yu XQ; Leow CC; Gibson N; Wilson S; Stover CK; Wu H; Gao C; Dimasi N
    MAbs; 2017; 9(2):240-256. PubMed ID: 27981887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
    Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
    J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system.
    Han L; Chen J; Ding K; Zong H; Xie Y; Jiang H; Zhang B; Lu H; Yin W; Gilly J; Zhu J
    Sci Rep; 2017 Aug; 7(1):8360. PubMed ID: 28827777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-Engineering.
    Xu H; Guo H; Cheung IY; Cheung NK
    Cancer Immunol Res; 2016 Jul; 4(7):631-8. PubMed ID: 27197064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of Cancer Cell Adhesion, Migration and Proliferation by a Bispecific Antibody that Targets two Distinct Epitopes on αv Integrins.
    Gallo E; Kelil A; Haughey M; Cazares-Olivera M; Yates BP; Zhang M; Wang NY; Blazer L; Carderelli L; Adams JJ; Kossiakoff AA; Wells JA; Xie W; Sidhu SS
    J Mol Biol; 2021 Jul; 433(15):167090. PubMed ID: 34090922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation.
    Shen Y; Zeng L; Novosyadlyy R; Forest A; Zhu A; Korytko A; Zhang H; Eastman SW; Topper M; Hindi S; Covino N; Persaud K; Kang Y; Burtrum D; Surguladze D; Prewett M; Chintharlapalli S; Wroblewski VJ; Shen J; Balderes P; Zhu Z; Snavely M; Ludwig DL
    MAbs; 2015; 7(5):931-45. PubMed ID: 26073904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activatable bispecific liposomes bearing fibroblast activation protein directed single chain fragment/Trastuzumab deliver encapsulated cargo into the nuclei of tumor cells and the tumor microenvironment simultaneously.
    Tansi FL; Rüger R; Böhm C; Steiniger F; Kontermann RE; Teichgraeber UK; Fahr A; Hilger I
    Acta Biomater; 2017 May; 54():281-293. PubMed ID: 28347861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models.
    Fan J; Zhuang X; Yang X; Xu Y; Zhou Z; Pan L; Chen S
    Signal Transduct Target Ther; 2021 Sep; 6(1):320. PubMed ID: 34475375
    [No Abstract]   [Full Text] [Related]  

  • 35. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.
    Smith EJ; Olson K; Haber LJ; Varghese B; Duramad P; Tustian AD; Oyejide A; Kirshner JR; Canova L; Menon J; Principio J; MacDonald D; Kantrowitz J; Papadopoulos N; Stahl N; Yancopoulos GD; Thurston G; Davis S
    Sci Rep; 2015 Dec; 5():17943. PubMed ID: 26659273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.
    Yu Y; Chen Y; Ding G; Wang M; Wu H; Xu L; Rui X; Zhang Z
    Biochem Biophys Res Commun; 2015 Aug; 464(1):154-60. PubMed ID: 26093299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of biologic activity of two anti-PSA/anti-CD3 bispecific single-chain antibodies].
    Wang D; Wu GJ; Wang H; Wu WZ; Yang SL; Tan JM
    Zhonghua Nan Ke Xue; 2007 Jan; 13(1):8-12. PubMed ID: 17302025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
    Hammond SA; Lutterbuese R; Roff S; Lutterbuese P; Schlereth B; Bruckheimer E; Kinch MS; Coats S; Baeuerle PA; Kufer P; Kiener PA
    Cancer Res; 2007 Apr; 67(8):3927-35. PubMed ID: 17440108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time resolved native ion-mobility mass spectrometry to monitor dynamics of IgG4 Fab arm exchange and "bispecific" monoclonal antibody formation.
    Debaene F; Wagner-Rousset E; Colas O; Ayoub D; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S
    Anal Chem; 2013 Oct; 85(20):9785-92. PubMed ID: 24007193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.